Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Generic Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:HSP
- CUSIP: 44106010
- Web: www.hospira.com/
- 50 Day Moving Avg: $90.00
- 200 Day Moving Avg: $88.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 24.58
- P/E Growth: 0
- Net Margins: 12.15%
- Return on Equity: 16.51%
- Return on Assets: 8.65%
Frequently Asked Questions for Hospira (NYSE:HSP)
What is Hospira's stock symbol?
Hospira trades on the New York Stock Exchange (NYSE) under the ticker symbol "HSP."
How were Hospira's earnings last quarter?
Hospira, Inc. (NYSE:HSP) released its earnings results on Wednesday, July, 29th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.07. The firm earned $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Hospira had a return on equity of 16.51% and a net margin of 12.15%. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.72 earnings per share. View Hospira's Earnings History.
Who are some of Hospira's key competitors?
Some companies that are related to Hospira include Illumina (ILMN), Smith & Nephew plc (SN), Omnicare (OCR), Bio-Rad Laboratories (BIO), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Catalent (CTLT), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV), Enerplus Corp (ERF), Axovant Sciences Ltd (AXON), Hikma Pharmaceuticals Plc (HIK) and BTG plc (BTG).
How do I buy Hospira stock?
Shares of Hospira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hospira's stock price today?
MarketBeat Community Rating for Hospira (NYSE HSP)MarketBeat's community ratings are surveys of what our community members think about Hospira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Hospira stock can currently be purchased for approximately $89.95.
Consensus Ratings for Hospira (NYSE:HSP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Hospira (NYSE:HSP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Hospira (NYSE:HSP)Earnings History by Quarter for Hospira (NYSE HSP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/29/2015||Q215||$0.78||$0.85||$1.18 billion||$1.20 billion||View||N/A|
|4/28/2015||Q115||$0.51||$0.97||$1.08 billion||$1.18 billion||View||N/A|
|2/12/2015||Q414||$0.41||$0.53||$1.12 billion||$1.13 billion||View||Listen|
|11/6/2014||Q314||$0.53||$0.74||$1.08 million||$1.15 billion||View||Listen|
|7/30/2014||Q214||$0.56||$0.72||$1.05 billion||$1.14 billion||View||Listen|
|4/30/2014||Q114||$0.49||$0.60||$1.02 billion||$1.10 billion||View||Listen|
|2/12/2014||Q413||$0.50||$0.51||$1.06 billion||$1.10 billion||View||Listen|
|7/31/2013||Q2 2013||$0.51||$0.55||$1.03 billion||$1.03 billion||View||Listen|
|5/1/2013||Q1 2013||$0.44||$0.52||$979.33 million||$884.00 million||View||Listen|
|2/13/2013||Q4 2012||$0.54||$0.55||$1.04 billion||$1.10 billion||View||Listen|
|11/7/2012||Q312||$0.45||$0.47||$987.67 million||$994.00 million||View||N/A|
Earnings Estimates for Hospira (NYSE:HSP)
Current Year EPS Consensus Estimate: $3.16 EPS
Next Year EPS Consensus Estimate: $3.66 EPS
Dividend History for Hospira (NYSE:HSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hospira (NYSE:HSP)Insider Trades by Quarter for Hospira (NYSE:HSP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/2/2015||Matthew R Stober||SVP||Sell||21,833||$87.49||$1,910,169.17|| |
|2/27/2015||Matthew R Stober||SVP||Sell||25,338||$87.47||$2,216,314.86|| |
|2/17/2015||Thomas E Werner||CFO||Sell||1,566||$87.35||$136,790.10|| |
|1/15/2015||Thomas E Werner||CFO||Sell||10,000||$61.56||$615,600.00|| |
|1/12/2015||Matthew R Stober||SVP||Sell||2,000||$61.80||$123,600.00|| |
|12/15/2014||Thomas E Werner||CFO||Sell||10,000||$60.86||$608,600.00|| |
|12/2/2014||Richard J Hoffman||CAO||Sell||21,850||$60.32||$1,317,992.00|| |
|11/25/2014||Marc J Yoskowitz||SVP||Sell||11,523||$59.93||$690,573.39|| |
|11/24/2014||Kenneth F Meyers||SVP||Sell||46,250||$59.66||$2,759,275.00|| |
|11/17/2014||Thomas E Werner||CFO||Sell||10,000||$57.73||$577,300.00|| |
|9/15/2014||Thomas E Werner||CFO||Sell||10,000||$52.74||$527,400.00|| |
|8/15/2014||Thomas E Werner||CFO||Sell||10,000||$55.13||$551,300.00|| |
|7/15/2014||Thomas E Werner||CFO||Sell||10,000||$51.50||$515,000.00|| |
|6/16/2014||Thomas E Werner||CFO||Sell||10,000||$50.82||$508,200.00|| |
|5/21/2014||Thomas Werner||CFO||Sell||30,000||$47.98||$1,439,400.00|| |
|5/16/2014||Connie Curran||Director||Sell||2,000||$47.44||$94,880.00|| |
|5/14/2014||Barbara Bowles||Director||Sell||2,000||$47.77||$95,540.00|| |
|5/13/2014||Richard Hoffman||CAO||Sell||15,000||$48.07||$721,050.00|| |
|5/12/2014||Brian Smith||SVP||Sell||40,000||$48.00||$1,920,000.00|| |
|3/14/2014||Matthew Stober||SVP||Sell||19,217||$42.28||$812,494.76|| |
|2/26/2014||Thomas Werner||CFO||Sell||20,000||$42.53||$850,600.00|| |
|9/11/2013||Richard J Hoffman||CAO||Sell||9,850||$39.38||$387,893.00|| |
|8/16/2013||Matthew Stober||SVP||Sell||4,990||$40.12||$200,198.80|| |
|6/7/2013||Sumant Ramachandra||SVP||Sell||23,702||$35.69||$845,924.38|| |
Headline Trends for Hospira (NYSE:HSP)
Latest Headlines for Hospira (NYSE:HSP)
Hospira (HSP) Chart for Wednesday, September, 20, 2017